Aura Biosciences
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
80 Guest St, Boston, Massachusetts, 0213...Phone Number
(617) 500-8864Website
www.aurabiosciences.comRevenue
$38.1 MillionStock Symbol
AURAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Aura Biosciences
Aura Biosciences is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.Explore more
Aura Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aura Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Aura Biosciences launches new products
Check out if Aura Biosciences is spiking on competitors!
Earning: See what the market has to say on Aura Biosciences recently announced quarterly report
Check if Aura Biosciences has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Aura Biosciences
Aura Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Aura Biosciences had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Aura Biosciences has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Aura Biosciences as Masked Content
Find more new buyers
Compare Similar Companies to Aura Biosciences
Compare insights from companies similar to Aura Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aura Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aura Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aura Biosciences.
Aura Biosciences financials insights
Gather financial insights about Aura Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$4M
2015
Series B
$21M
2016
Debt
$11.5M
2017
Series C
$30M
2019
Series D
$40M
2021
Other Financing Round
$80M
Stock Offering
$76M
2025
Stock/Share Issuance
$69.9M
Aura Biosciences Tech Stack
A closer look at the technologies used by Aura Biosciences
Most Recent Scoops
Earnings
Aura Biosciences has designed the CoMpass Phase III trial as a 3-arm study enrolling approximately 100 patients with early choroidal melanoma, with a primary efficacy analysis evaluating an 80 microgram dose of bel-sar versus a sham injection via a 15-month landmark analysis of time to tumor progression, and a key secondary endpoint measuring a composite of time to tumor progression or visual acuity failure, whichever occurs first.
Clinical Operations
Earnings
Aura Biosciences has received a Special Protocol Assessment (SPA) from the FDA for the CoMpass trial, covering agreement on the study design, size, and the efficacy and safety analyses required to support registration, providing the company with a high degree of regulatory clarity ahead of its planned BLA filing.
Compliance, Clinical Operations, Regulations
Earnings
Aura Biosciences has reported that its Phase II study of bel-sar via suprachoroidal injection demonstrated 80% tumor control and 90% visual acuity preservation at 12 months in the efficacious dose range, along with a highly favorable safety profile.
Medical Research, Pharmaceuticals, Clinical Operations
Facilities Relocation / Expansion
Aura Biosciences is conducting a safety and feasibility study of bel-sar for ocular surface cancers using intra-tumoral injection at the front of the eye with anterior laser activation,representing a new route of administration distinct from the suprachoroidal injection used in the company's choroidal melanoma program.
Medical Research
Project
Medical Research, Clinical Operations
Aura Biosciences News & Media
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trialAura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company’s initial development focus while also discussing ongoing work in non-muscle invasive bladdeAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura’s new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are consistent with the previously disclosed terAura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aura Biosciences
Sign Up For FreeTo access detailed company insights
Aura Biosciences is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.... Read More
